Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP

Data are presented on pharmacodynamic (PD) method validation and preliminary clinical qualification of three PD biomarker assays. M65 Elisa, which quantitates different forms of circulating cytokeratin 18 (CK18) as putative surrogate markers of both apoptotic and nonapoptotic tumour cell death, was...

Descripción completa

Detalles Bibliográficos
Autores principales: Cummings, J, Ranson, M, LaCasse, E, Ganganagari, J R, St-Jean, M, Jayson, G, Durkin, J, Dive, C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360484/
https://www.ncbi.nlm.nih.gov/pubmed/16804528
http://dx.doi.org/10.1038/sj.bjc.6603220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360484/
https://www.ncbi.nlm.nih.gov/pubmed/16804528
http://dx.doi.org/10.1038/sj.bjc.6603220

Ejemplares similares